RecruitingPHASE1, PHASE2NCT04796012

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Studying Rhabdomyosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Texas Southwestern Medical Center
Principal Investigator
Arhanti Sadanand, MD, MD
University of Texas Southwestern Medical Center
Intervention
Atezolizumab(drug)
Enrollment
23 target
Eligibility
30 years · All sexes
Timeline
2023 – 2027

Study locations (7)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04796012 on ClinicalTrials.gov

Other trials for Rhabdomyosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Rhabdomyosarcoma →

← Back to all trials